Clinical trial

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07287150

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-03-11

PhasePHASE2

Study timeline

Study start (actual)2026-03-11Date precision: day

Registry last updated2026-10-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Castration-Resistant Prostate Cancerunresolved

Interventions

InavolisibDRUG · verified · RxNorm: inavolisib

EnzalutamideDRUG · verified · RxNorm: enzalutamide

AbirateroneDRUG · verified · RxNorm: abiraterone

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

SeoulSouth Korea4 MontrealQuebec, Canada2 MilanLombardy, Italy2 Los AngelesCalifornia, United States1 TorontoOntario, Canada1 San FranciscoCalifornia, United States1 MadridSpain1 The BronxNew York, United States1 HamburgGermany1 ValenciaSpain1 MarseilleFrance1 LyonFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07287150 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.